Anika Therapeutics is a specialty medical device and biologics company focused on treating orthopedic conditions using hyaluronic acid (HA), a naturally occurring polymer with lubricating and regenerative properties. Anika's core products fall into two categories: OA pain management and regenerative solutions. On the OA pain side, Anika makes Monovisc, Orthovisc, and Cingal — HA-based viscosupplements injected into arthritic joints to relieve osteoarthritis pain. In the U.S., Anika sells Monovisc and Orthovisc exclusively through Johnson & Johnson MedTech under long-term licensing agreements, manufacturing the products and receiving transfer pricing plus royalties tied to J&J's end-user pricing — meaning Anika has no control over U.S. pricing. Outside the U.S., Anika sells directly through a global distributor network. Cingal, which combines HA with a fast-acting steroid for both immediate and longer-term pain relief, is approved in 50+ countries but not yet in the U.S. On the regenerative side, Anika sells the Integrity Implant System, an HA-based scaffold for tendon repair, through its own U.S. sales force and distributors. Hyalofast, an HA scaffold for cartilage repair sold in 30+ countries, is under FDA review for U.S. approval. Anika's near-term profitability is heavily influenced by J&J's U.S. pricing decisions and manufacturing yields at its single Bedford, MA facility. Anika's growth strategy centers on expanding the commercial channel, reducing J&J dependence, and pursuing U.S. approvals for Cingal and Hyalofast.